PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 88182290 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 108 |
MARK SECTION | |
MARK | RIABNI (see, http://uspto.report/TM/88182290/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | RIABNI |
OWNER SECTION (current) | |
NAME | Amgen Inc. |
INTERNAL ADDRESS | Trademark Operations - MS-28-5A |
MAILING ADDRESS | One Amgen Center Drive |
CITY | Thousand Oaks |
STATE | California |
ZIP/POSTAL CODE | 91320-1799 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
PHONE | 805-447-3278 |
XXXX | |
OWNER SECTION (proposed) | |
NAME | Amgen Inc. |
INTERNAL ADDRESS | Trademark Operations - MS-28-5A |
MAILING ADDRESS | One Amgen Center Drive |
CITY | Thousand Oaks |
STATE | California |
ZIP/POSTAL CODE | 91320-1799 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
PHONE | 805-447-3278 |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Timothy J. Gaul |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | tmops@amgen.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | elemoine@amgen.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Timothy J. Gaul |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | tmops@amgen.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | elemoine@amgen.com |
DOCKET/REFERENCE NUMBER | TM-1826-US-1 |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the blood, skin, bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantation |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 3 |
ONGOING EFFORT | product or service research or development |
ALLOWANCE MAIL DATE | 11/05/2019 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 1 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 125 |
TOTAL AMOUNT | 125 |
SIGNATURE SECTION | |
SIGNATURE | /Elsa D. Lemoine/ |
SIGNATORY'S NAME | Lemoine, Elsa D. |
SIGNATORY'S POSITION | Attorney of Record, California Bar member |
DATE SIGNED | 04/05/2021 |
SIGNATORY'S PHONE NUMBER | 805-447-3278 |
SIGNATURE METHOD | Sent to third party for signature |
FILING INFORMATION | |
SUBMIT DATE | Mon Apr 05 16:48:04 ET 2021 |
TEAS STAMP | USPTO/ESU-XXX.XXX.XXX.X-2 0210405164804733822-88182 290-77025349fce94821ebe35 f97197eadd24b7472dea941d1 c17fde7639456ecf4d-DA-480 22557-2021040516224300517 8 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |